Boston Common Asset Management LLC Makes New $3.32 Million Investment in Abbott Laboratories $ABT

Key Points

• Boston Common Asset Management LLC made a new investment of approximately $3.32 million in Abbott Laboratories by acquiring 24,381 shares during the 2nd quarter.
• Abbott Laboratories reported a 7.4% increase in revenue year-over-year, totaling $11.14 billion, and met analysts' EPS estimates at $1.26.
• The company has announced a quarterly dividend of $0.59 per share, representing a 1.8% dividend yield, with payment scheduled for November 17th.

Boston Common Asset Management LLC acquired a new position in shares of Abbott Laboratories (NYSE:ABT - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 24,381 shares of the healthcare product maker's stock, valued at approximately $3,316,000.

Several other hedge funds also recently made changes to their positions in ABT. Brighton Jones LLC grew its holdings in shares of Abbott Laboratories by 10.1% during the fourth quarter. Brighton Jones LLC now owns 51,719 shares of the healthcare product maker's stock worth $5,850,000 after purchasing an additional 4,755 shares during the last quarter. First National Corp MA ADV grew its holdings in shares of Abbott Laboratories by 1.1% during the first quarter. First National Corp MA ADV now owns 11,270 shares of the healthcare product maker's stock worth $1,495,000 after purchasing an additional 123 shares during the last quarter. Impact Capital Partners LLC grew its holdings in shares of Abbott Laboratories by 3.9% during the first quarter. Impact Capital Partners LLC now owns 21,810 shares of the healthcare product maker's stock worth $2,893,000 after purchasing an additional 826 shares during the last quarter. Congress Asset Management Co. grew its holdings in shares of Abbott Laboratories by 6.3% during the first quarter. Congress Asset Management Co. now owns 3,529 shares of the healthcare product maker's stock worth $468,000 after purchasing an additional 210 shares during the last quarter. Finally, Sara Bay Financial boosted its stake in shares of Abbott Laboratories by 9.2% during the first quarter. Sara Bay Financial now owns 8,416 shares of the healthcare product maker's stock worth $1,101,000 after buying an additional 709 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Insider Activity

In other news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction that occurred on Friday, August 8th. The shares were sold at an average price of $134.55, for a total transaction of $746,752.50. Following the completion of the sale, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company's stock.

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $134.49 on Friday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The company has a market cap of $234.07 billion, a P/E ratio of 16.85, a PEG ratio of 2.55 and a beta of 0.69. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a 50-day moving average price of $131.94 and a 200 day moving average price of $131.36.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 EPS for the quarter, meeting analysts' consensus estimates of $1.26. The firm had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The firm's revenue was up 7.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.14 earnings per share. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Research analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be given a dividend of $0.59 per share. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories's dividend payout ratio (DPR) is presently 29.57%.

Analyst Upgrades and Downgrades

ABT has been the subject of several recent research reports. William Blair upgraded shares of Abbott Laboratories to a "strong-buy" rating in a research note on Thursday, July 17th. Royal Bank Of Canada increased their target price on shares of Abbott Laboratories from $145.00 to $147.00 and gave the stock an "outperform" rating in a research note on Tuesday, July 15th. Weiss Ratings reiterated a "buy (b)" rating on shares of Abbott Laboratories in a research note on Saturday, September 27th. Jefferies Financial Group upgraded shares of Abbott Laboratories from a "hold" rating to a "buy" rating and increased their target price for the stock from $143.00 to $145.00 in a research note on Friday, July 18th. Finally, BTIG Research decreased their target price on shares of Abbott Laboratories from $148.00 to $145.00 and set a "buy" rating for the company in a research note on Friday, July 18th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $145.39.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.